Navigation Links
Chimerix Raises $16.1 Million in Series E Financing

RESEARCH TRIANGLE PARK, N.C., Aug. 11 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, today announced the completion of a $16.1 million Series E financing. Leading life science venture capital investors Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company participated in this insider round.

Proceeds from the financing will primarily be used to expand Chimerix's clinical development program for its lead drug candidate, CMX001. CMX001 has shown activity in early clinical studies as a broad-spectrum antiviral drug, and is currently being evaluated for the treatment of cytomegalovirus (CMV) and BK virus in Phase II clinical trials. CMX001 is also being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination. In addition, Chimerix expects to advance CMX157, an anti-HIV drug, into Phase I clinical development and to continue work on a library of compounds that have shown extremely potent activity against a range of viral diseases including hepatitis C.

"Chimerix's robust pharmaceutical product pipeline and world-class expertise in the area of antiviral medicines offer truly novel and promising approaches for the treatment of a number of challenging viral and inflammatory diseases," said Seth Rudnick, M.D., of Canaan Partners and Co-Chairman of the company's Board of Directors. "We believe that this financing will enable the Chimerix team to continue doing what they do best - identify, optimize and develop important new antiviral medicines that address significant therapeutic markets and may prove valuable in our nation's biodefense strategy."

"We are pleased by the consistent support Chimerix has received from such a premier group of experienced life science investors," said George Painter, Ph.D., Chimerix's President and Chief Executive Officer. "These funds will enable us to drive forward clinical development of our promising drug candidates to a point where we are well-positioned to make strategic decisions about the best course for late-stage clinical development, as well as potential partnering with leading pharmaceutical companies."

About Chimerix

Chimerix, Inc., discovers, develops and commercializes antiviral therapeutics with enhanced pharmaceutical properties for the treatment of a range of life-threatening diseases. Leveraging a powerful lipid technology, Chimerix is able to develop drug candidates with oral availability or topical applications with increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events. The company's lead compound, CMX001, has shown promise as a broad-spectrum antiviral drug and is currently being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination, as well as for the treatment of infections that cause morbidity and mortality in immunocompromised patients such as cytomegalovirus (CMV) and BK virus. Chimerix's pipeline includes an anti-HIV drug, CMX157, in late-stage preclinical studies. Chimerix is also advancing programs in hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. For further information, please visit the company's website at

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, Disappointed by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bills Prognosis
2. High cholesterol in midlife raises risk of late-life dementia, Kaiser Permanente study finds
3. High Cholesterol in Midlife Raises Risk of Late-Life Dementia, Kaiser Permanente Study Finds
4. HMS Holdings Corp. Announces Q2 2009 Results and Raises 2009 Guidance
5. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
6. Be a Hero For Babies Day Raises $2.6 Million for March of Dimes
7. Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance
8. Universal Health Services, Inc. Reports Significant Increases In 2009 Second Quarter and Six-Month Earnings, Raises Full Year Guidance
9. aTyr Pharma Raises an Additional $12 Million
10. Applied Physiology Raises $5 Million for Navigator™ Market Launch
11. Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
Post Your Comments:
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number ... first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired ... Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms ... hands, and dry skin. But many people who find their cholesterol levels and weight ... of their thyroid, especially if they don’t have any of the other symptoms. , ...
(Date:11/25/2015)... ... 2015 , ... Students and parents have something to be thankful for this ... Impact awards. California Casualty is proud to support the contest designed to ... reckless driving, the number one killer of young drivers. , Almost 1,000 entries ...
(Date:11/24/2015)... ... 2015 , ... Eric C. Seidel, DMD and Stephanie DeFilippo, ... revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses light energy ... dentist in Gettysburg, PA . From routine visits to cosmetic treatments, laser dentistry ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: AGN ) ... New York State Attorney General,s Office ... Act, and other statutes with the Attorney General over the ... cease marketing and selling the now generic version of memantine ... no liability, has released its counterclaims against New ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... - Will Also Offer Point -of- ... --> - Will Also Offer Point ... --> - Will Also Offer ... (CME) Elsevier , a world-leading provider of ... diagnostic imaging textbooks and decision support tools, as well as prominent ...
Breaking Medicine Technology: